<DOC>
	<DOCNO>NCT02040792</DOCNO>
	<brief_summary>This study evaluate safety efficacy four dose TD-4208 placebo product administer daily 28 day use jet nebulizer patient moderate severe chronic obstructive pulmonary disease .</brief_summary>
	<brief_title>A 28-Day Parallel Group Study TD-4208 Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Subject male female subject 40 year age old Subject must negative pregnancy test , must prepare use effective contraception childbearing potential Subject capable perform reproducible spirometry maneuver Subject postbronchodilator FEV1/FVC ratio &lt; 0.7 Subject moderatetosevere stable COPD ( Stage 2 3 accord GOLD Guidelines ) Subject postbronchodilator FEV1 great equal 30 % le 80 % predict normal Subject current past smoking history least 10 packyears . Subject significant respiratory disease disorder COPD would affect interpretation data study Subject history reaction hypersensitivity inhale nebulized anticholinergic betaagonist agent Subject suffers medical condition would preclude use inhaled anticholinergic agent Subject hospitalize COPD pneumonia within 12 week Subject require longterm oxygen therapy ( &gt; 15 hour day )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
</DOC>